Fundie's stock tips need to pass the dinner party test

John Pinkel backs his conviction in overlooked stocks, from AI chipmaker SK Hynix to sportswear brand ASICS. David Rogers examines the Indus Capital fund manager’s contrarian approach and how he spots opportunities others miss.

David Rogers

Fundie's stock tips need to pass the dinner party test

October 23, 2026
John Pinkel backs his conviction in overlooked stocks, from AI chipmaker SK Hynix to sportswear brand ASICS. David Rogers examines the Indus Capital fund manager’s contrarian approach and how he spots opportunities others miss.
Read Transcript

When fund manager John Pinkel tells people at dinner parties that he is buying SK Hynix, he knows what is coming.

‍

“Five people would immediately tell you all the reasons it's a bad idea,” he says.

‍

“That's usually a necessary, but not sufficient, condition for a good investment idea.”

‍

It is a line that sums up his style. Pinkel is a partner and portfolio manager at Indus Capital, an Asia-Pacific equities manager with about $US6bn ($8.6bn) under management. He has run the firm's pan-Asia Select Fund since 2009. His concentrated, long-only portfolio of roughly 35 stocks covers about half the world's population, a third of global output and a quarter of global market capitalisation.

‍

Pinkel's conviction in Hynix goes back to 2019, when Indus made a deliberate call to build a long-term position based on the growing strategic importance of memory chips, long before artificial intelligence became a buzzword on every trading desk.

‍

Indus deliberately avoided Samsung Electronics, despite its index weight.

‍

“We just wanted pure memory exposure,” Pinkel says.

‍

That patience paid off last year and into mid-2025, as AI infrastructure spending drove memory prices higher. Indus took profits in May and June, then became a buyer again as the stock slid. Pinkel says that, using smoothed two-year forward earnings, Hynix peaked in June at about seven times earnings and now trades at roughly three times.

‍

“There's a lot for people to worry about, and that worry is exactly what creates the opportunity,” he says.

‍

Pinkel's path to Indus began in 1989, when he moved to Taiwan for intensive Mandarin training, then spent time in mainland China in the aftermath of the Tiananmen Square crackdown. Stints followed in Hong Kong, Shanghai, Seoul and Taipei, including running Citigroup's equities business in Taiwan. He joined Indus 24 years ago.

‍

Along the way, he married a lawyer from Brisbane's southern suburbs, in the same electorate once held by former prime minister Kevin Rudd, a fellow Mandarin speaker.

‍

The couple later owned a cattle property outside Gympie in the Sunshine Coast hinterland. Thirteen years ago they moved to Silicon Valley, a decision Pinkel calls “serendipitous”.

‍

Living near the headquarters of companies such as Apple, Nvidia and Netflix has given his Asia-focused team a key vantage point. Pinkel finds senior Asian executives are often easier to meet in San Francisco or New York than in Tokyo. And R&D heads often have sharper insight into a company's future than its chief executive.

‍

Pinkel's dinner party test - that good ideas usually attract scepticism - shows up repeatedly in his best-performing positions.

‍

One is E Ink, an obscure Taiwanese company making the epaper display technology used in e-readers such as Kindles. Indus found it about a decade ago, well before wider adoption. “They have wonderful display technology that uses about 1 per cent of the power of TFT LCD,” Pinkel says. The firm expects it to spread into more products over time.

‍

Another is ASICS, the Japanese sportswear brand. Indus bought in when the North American business was widely seen as broken, drawing on two New York-based analysts who understood exactly what had gone wrong there in 2015 and 2016 - and that it was fixable.

‍

Indus also backed the revival of the brand's heritage “Onitsuka Tiger” fashion line.

‍

The position has returned six times Indus's money over six years.

‍

“We're Asia-based, but we're able to look at things from a global perspective,” Pinkel says.

‍

Japanese conglomerate Hitachi fits the same pattern.

‍

“A totally different company” to 15 years ago, it is now driven significantly by a power grid business bought from Switzerland's ABB, feeding growing demand from renewables and data centres.

‍

Indus is also the largest shareholder, as a firm, in regional lender Suruga Bank, alongside a stake in Mizuho.

‍

Medical technology group Olympus has been a repeat trade: Indus bought heavily after an accounting scandal resulted in the shares sinking about 80 per cent in 2012, sold out, then returned this year after a fresh slump.

‍

“We've swooped in twice to buy Olympus on the lows,” Pinkel says of a business now built around endoscopes and surgical devices.

‍

A similar story applies to Fujitsu, where Indus became a shareholder nine years ago, betting on Japan's historic under-investment in corporate technology.

‍

A colleague now sits on Fujitsu's board, reflecting an “engagement” style of investing rather than public activism.

‍

“We can be tough,” Pinkel says. “We're just not going to be public about it.”

‍

On resources, Pinkel says Indus prefers Australian miners such as BHP over emerging market rivals, citing governance standards.

‍

“Australia probably has the highest standards in the world for environmental concern and engagement with local communities,” he says.

‍

Pinkel's connection to the conference at which he was interviewed, Sohn Hearts & Minds, runs far deeper than investing. His father, Donald Pinkel, was the founding medical director of St Jude Children's Research Hospital in Memphis. At the time, childhood leukaemia was considered close to a death sentence. Donald Pinkel pioneered a combined treatment approach that turned it into a curable disease, a breakthrough that became the template for leukaemia treatment worldwide.

‍

The 2026 Sohn Hearts & Minds Investment Leaders Conference will be held in Queenstown, New Zealand on Friday, November 6. It will be the first time the event has been staged outside of Australia.

‍

The Australian is a media partner. Tickets can be purchased at sohnheartsandminds.com.au

‍

This article was originally posted by The Australian here. Licensed by Copyright Agency. You must not copy this work without permission.

‍

When fund manager John Pinkel tells people at dinner parties that he is buying SK Hynix, he knows what is coming.

‍

“Five people would immediately tell you all the reasons it's a bad idea,” he says.

‍

“That's usually a necessary, but not sufficient, condition for a good investment idea.”

‍

It is a line that sums up his style. Pinkel is a partner and portfolio manager at Indus Capital, an Asia-Pacific equities manager with about $US6bn ($8.6bn) under management. He has run the firm's pan-Asia Select Fund since 2009. His concentrated, long-only portfolio of roughly 35 stocks covers about half the world's population, a third of global output and a quarter of global market capitalisation.

‍

Pinkel's conviction in Hynix goes back to 2019, when Indus made a deliberate call to build a long-term position based on the growing strategic importance of memory chips, long before artificial intelligence became a buzzword on every trading desk.

‍

Indus deliberately avoided Samsung Electronics, despite its index weight.

‍

“We just wanted pure memory exposure,” Pinkel says.

‍

That patience paid off last year and into mid-2025, as AI infrastructure spending drove memory prices higher. Indus took profits in May and June, then became a buyer again as the stock slid. Pinkel says that, using smoothed two-year forward earnings, Hynix peaked in June at about seven times earnings and now trades at roughly three times.

‍

“There's a lot for people to worry about, and that worry is exactly what creates the opportunity,” he says.

‍

Pinkel's path to Indus began in 1989, when he moved to Taiwan for intensive Mandarin training, then spent time in mainland China in the aftermath of the Tiananmen Square crackdown. Stints followed in Hong Kong, Shanghai, Seoul and Taipei, including running Citigroup's equities business in Taiwan. He joined Indus 24 years ago.

‍

Along the way, he married a lawyer from Brisbane's southern suburbs, in the same electorate once held by former prime minister Kevin Rudd, a fellow Mandarin speaker.

‍

The couple later owned a cattle property outside Gympie in the Sunshine Coast hinterland. Thirteen years ago they moved to Silicon Valley, a decision Pinkel calls “serendipitous”.

‍

Living near the headquarters of companies such as Apple, Nvidia and Netflix has given his Asia-focused team a key vantage point. Pinkel finds senior Asian executives are often easier to meet in San Francisco or New York than in Tokyo. And R&D heads often have sharper insight into a company's future than its chief executive.

‍

Pinkel's dinner party test - that good ideas usually attract scepticism - shows up repeatedly in his best-performing positions.

‍

One is E Ink, an obscure Taiwanese company making the epaper display technology used in e-readers such as Kindles. Indus found it about a decade ago, well before wider adoption. “They have wonderful display technology that uses about 1 per cent of the power of TFT LCD,” Pinkel says. The firm expects it to spread into more products over time.

‍

Another is ASICS, the Japanese sportswear brand. Indus bought in when the North American business was widely seen as broken, drawing on two New York-based analysts who understood exactly what had gone wrong there in 2015 and 2016 - and that it was fixable.

‍

Indus also backed the revival of the brand's heritage “Onitsuka Tiger” fashion line.

‍

The position has returned six times Indus's money over six years.

‍

“We're Asia-based, but we're able to look at things from a global perspective,” Pinkel says.

‍

Japanese conglomerate Hitachi fits the same pattern.

‍

“A totally different company” to 15 years ago, it is now driven significantly by a power grid business bought from Switzerland's ABB, feeding growing demand from renewables and data centres.

‍

Indus is also the largest shareholder, as a firm, in regional lender Suruga Bank, alongside a stake in Mizuho.

‍

Medical technology group Olympus has been a repeat trade: Indus bought heavily after an accounting scandal resulted in the shares sinking about 80 per cent in 2012, sold out, then returned this year after a fresh slump.

‍

“We've swooped in twice to buy Olympus on the lows,” Pinkel says of a business now built around endoscopes and surgical devices.

‍

A similar story applies to Fujitsu, where Indus became a shareholder nine years ago, betting on Japan's historic under-investment in corporate technology.

‍

A colleague now sits on Fujitsu's board, reflecting an “engagement” style of investing rather than public activism.

‍

“We can be tough,” Pinkel says. “We're just not going to be public about it.”

‍

On resources, Pinkel says Indus prefers Australian miners such as BHP over emerging market rivals, citing governance standards.

‍

“Australia probably has the highest standards in the world for environmental concern and engagement with local communities,” he says.

‍

Pinkel's connection to the conference at which he was interviewed, Sohn Hearts & Minds, runs far deeper than investing. His father, Donald Pinkel, was the founding medical director of St Jude Children's Research Hospital in Memphis. At the time, childhood leukaemia was considered close to a death sentence. Donald Pinkel pioneered a combined treatment approach that turned it into a curable disease, a breakthrough that became the template for leukaemia treatment worldwide.

‍

The 2026 Sohn Hearts & Minds Investment Leaders Conference will be held in Queenstown, New Zealand on Friday, November 6. It will be the first time the event has been staged outside of Australia.

‍

The Australian is a media partner. Tickets can be purchased at sohnheartsandminds.com.au

‍

This article was originally posted by The Australian here. Licensed by Copyright Agency. You must not copy this work without permission.

‍

Disclaimer: This material has been prepared by The Australian, published on October 23, 2026. HM1 is not responsible for the content of linked websites or content prepared by third party. The inclusion of these links and third-party content does not in any way imply any form of endorsement by HM1 of the products or services provided by persons or organisations who are responsible for the linked websites and third-party content. This information is for general information only and does not consider the objectives, financial situation or needs of any person. Before making an investment decision, you should read the relevant disclosure document (if appropriate) and seek professional advice to determine whether the investment and information is suitable for you.

facebook
linkedin
All
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
November 5, 2024

Antipodes’ Ross says short-term wealth hinges on US election

The portfolio manager says defensive stocks pose a bigger risk than the magnificent seven for investors that are overexposed to the American sharemarket.

Read More
November 5, 2024

Concentration risk key for investors: Antipodes Partners’ Vihari Ross

The concentration risk in global stock indexes that has built up during the strong rise over the past year must now be a key consideration for global investors, according to Vihari Ross.

Read More
November 5, 2024

The fundie betting big on China – with help from AI

Mr Mehta is sticking to his well-worn strategy: he’s hunting for companies across Asia that aren’t battling intense competition and have management teams focused on costs, cash generation and high payouts to shareholders.

Read More
Beeneet Kothari is ready to shock the Sohn Hearts & Minds event.Beeneet Kothari is ready to shock the Sohn Hearts & Minds event.Beeneet Kothari is ready to shock the Sohn Hearts & Minds event.Beeneet Kothari is ready to shock the Sohn Hearts & Minds event.
October 29, 2024

Why this fundie wants you to ‘wince’ at his stock picks

When fund managers come to pitch their favourite stock at the annual Sohn Hearts & Minds conference, there are two ways they can go: they can play it safe, or they can take a risk and shock the room.

Read More
October 27, 2024

IFM Investors’ Rikki Bannan backs small cap investments to rebound after mixed performance

IFM Investors executive director Rikki Bannan believes this year could be a good one to invest in some select small cap stocks.

Read More
October 22, 2024

Meet the 2024 Conference Managers

Following a global search, the Conference Fund Manager Selection Committee is pleased to share eleven new managers for 2024.

Read More
October 21, 2024

Chris Kourtis is on a winning streak. Here’s his next ASX pick

Chris Kourtis of Ellerston Capital thinks he’s found another winner and thinks it’s the last chance to have a bite at the cherry before the strategy plays out.

Read More
Ellerston Capital portfolio manager Chris Kourtis. Picture: Britta CampionEllerston Capital portfolio manager Chris Kourtis. Picture: Britta CampionEllerston Capital portfolio manager Chris Kourtis. Picture: Britta CampionEllerston Capital portfolio manager Chris Kourtis. Picture: Britta Campion
October 21, 2024

Why Ellerston Capital’s Chris Kourtis plans to back a ‘hated’ stock

Chris Kourtis of Ellerston Capital plans to tip one of the “most hated” stocks in Australia when he presents at the 2024 Sohn Hearts & Minds Conference.

Read More
October 14, 2024

Alex Pollak champions rewards of disruptive investment

Alex Pollak’s funds management company Loftus Peak rode the Nvidia wave and he is now looking at more opportunities in disruptive industry stocks.

Read More
September 30, 2024

Missed out on Nvidia and Ozempic? This fundie says it’s never too late

Northcape Capital’s Fleur Wright is still kicking herself for not owning market darlings Nvidia and Novo Nordisk, the maker of the weight loss wonder drug Ozempic, before shares of those companies rocketed in 2023.

Read More
September 23, 2024

Scalar Gauge Fund founder Sumit Gautam cautious about over-hyped AI

Tech investor Sumit Gautam carefully avoids the word bubble when describing the investor frenzy surrounding the rise of artificial intelligence, but warns there are dangers of getting caught up in the hype.

Read More
September 9, 2024

The Wellcome Trust’s Nick Moakes made a 100-year bet. It’s paying off

Chief Investment Officer, Nick Moakes raised almost $3 billion at ultra-low rates. Sometimes the long view can be the most profitable.

Read More
September 5, 2024

Honesty the only policy that matters, says Wellcome Trust’s Nicholas Moakes

The chief investment officer of the London-based $71bn Wellcome Trust, Nick Moakes, has a simple rule for the trust’s investment team: “Never invest with anyone who is or has been or should have been in prison.”

Read More
September 5, 2024

Why Howard Marks says you’re making a big mistake

Howard Marks says investors must ignore manic depressive markets and focus on the bigger picture. Rates will be higher for longer and that will bring pain – and opportunity.

Read More
July 21, 2024

Investors ‘comfortable’ about a Trump presidency, despite volatility

Economists and market experts say the outcome of the US presidential election has been largely priced in by investors as softening inflation helps to buoy sharemarkets both globally and locally.

Read More
December 10, 2024

Professor Jane Butler: Sparking Hope for Spinal Cord Injuries

In this episode of the Hearts & Minds Podcast, we sit down with Professor Jane Butler to discuss her groundbreaking research into spinal cord injuries.

Read More
impact-podcasts
September 24, 2024

Asian Market Potential with Tom Naughton of Prusik

CIO Charlie Lanchester sits down with Tom Naughton, CIO of Prusik Investment Mgmt. Tom shares his investment philosophy, the opportunities and challenges in Asian markets, and how his 2023 conference stock pick, Swire Pacific (0019.HK), delivered an impressive 30% return.

Read More
investing
September 4, 2024

Building Hearts and Minds with Co-Founders Matthew Grounds and Guy Fowler

In this episode, co-founders Matthew Grounds AM and Guy Fowler OAM discuss their journey in building Hearts & Minds and its philanthropic model that has donated over $70 million to medical research.

Read More
investing
June 25, 2024

Navigating the Resource Sector with Jeremy Bond of Terra Capital

In this episode, we chat with Jeremy Bond, Founder of Terra Capital and HM1 Conference Fund Manager. Tune in for insights into the world of resource investments and the exciting opportunities that lie ahead.

Read More
investing
June 11, 2024

Prof. Nadia Badawi on Cerebral Palsy Breakthroughs and Neonatal Care

Dive deep into the groundbreaking work of Professor Nadia Badawi, an internationally recognised neonatologist and expert in Cerebral Palsy.

Read More
impact-podcasts
May 28, 2024

Investment Insights: Rikki Bannan on Top Picks and Trends

Join us for an engaging episode featuring Rikki Bannan, Portfolio Manager of IFM Investors and HM1 Conference Fund Manager. This episode explores Rikki's career journey, investment strategies, and her 2023 conference stock pick, Telix Pharmaceuticals (ASX.TLX).

Read More
investing
December 6, 2023

Peter Cooper talks building and instilling a culture of humility and excellence

In this episode, our guest is the renowned investor, Peter Cooper, founder and Chief Investment Officer of Cooper Investors (Core Fund Manager). A founding supporter of Hearts and Minds, Peter is a staunch advocate of our model and its philanthropic purpose, actively engaging in every facet of Hearts and Minds.

Read More
investing
November 28, 2023

Jun Bei Liu on her high conviction investment strategy

In this episode, HM1 Chief Investment Officer Charlie Lanchester is joined by Jun Bei Liu. Jun Bei is the Portfolio Manager of Tribeca’s Alpha Plus Fund and since taking over managing the Fund, she has quadrupled AUM.

Read More
investing
November 21, 2023

The world of rare genetic disease research

In this episode, we speak to Associate Professor Gina Ravenscroft. Gina is an Associate Professor in Neurogenetics at the Harry Perkins Institute of Medical Research in Perth. Her research interests are in rare genetic diseases, with a particular focus on neurogenetic diseases in babies and children.

Read More
impact-podcasts
November 14, 2023

Learn what makes a high conviction investment and how to avoid short-term noise

In this episode, our Core Fund Manager Magellan shares how they select top stocks for the HM1 portfolio.

Read More
investing
November 7, 2023

Delve into the world of kids critical care and trauma research

In thie episode, we are joined by Dr. Marino Festa, or Rino for short. He is the Medical Director of NSW Kids ECMO Referral Service and a senior specialist in Paediatric Intensive Care at Children’s Hospital at Westmead.

Read More
impact-podcasts
October 31, 2023

Where Regal's Phil King is searching for opportunities

HM1's CIO, Charlie Lanchester, talks to Phil King of Regal Funds about his passion for stocks, his ongoing search for opportunities, and some of the sectors he’s excited by right now. Phil King of Regal Funds, has been a tremendous supporter of Hearts & Minds since the beginning.

Read More
investing
October 24, 2023

Preventing recurrent miscarriages and birth defects

In this episode, CEO Paul Rayson is joined by renowned biomedical researcher Professor Sally Dunwoodie. Prof. Dunwoodie's groundbreaking work has revolutionised clinical practices and enabled genetic diagnostic tests worldwide. In 2017, her team achieved a double breakthrough with the potential to prevent recurrent miscarriages and various birth defects.

Read More
impact-podcasts
October 17, 2023

Nick Griffin on how he finds global winners

In this episode, CIO Charlie Lanchester chats with Nick Griffin, the founding partner and CIO of Munro Partners, one of HM1's Core Fund Managers. They go over his career to date, reflect on the lessons he’s learned, and trace the decisions that led to him starting Munro.

Read More
investing
October 10, 2023

How A/Prof Matt Call is teaching our body to kill cancer

In this episode, CEO Paul Rayson is joined by WEHI’s Associate Professor Matt Call to talk about his incredible research. Matt’s team teaches and trains the body's own immune cells to target and kill cancer cells.

Read More
impact-podcasts

No results found.

Please try a different search keyword or filter.